Cite
HARVARD Citation
Xin, W. et al. (2020). Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial. BMJ open. 10 (12), p. . [Online].